How We Think
Our Approach
Our Method
Insights
Let's Grow Together
How We Think
Our Approach
Our Method
Bullzeye 3D Framework
The Judgment Layer
Healthcare Growth Intelligence
Insights
AI Visibility
Commercialization
Executive Strategy
Let's Grow Together
Grow Together
Let's Grow Together

Healthcare Visibility Executive Scorecard

Purpose: This executive scorecard is a structured self-assessment, not the formal Healthcare Visibility Index. It helps leadership identify where a full evidence-based diagnostic may be warranted.

How to use the scorecard

Rate each statement from 0 to 5 using evidence available today. Zero means absent. Five means comprehensive, independently corroborated and monitored. If the team cannot point to evidence, score the statement lower rather than substituting confidence. Average the statements inside each dimension, convert to a percentage and give each dimension an equal 16.67-point weight.

Discoverability
  • [0-5] Priority audiences can find our services, expertise or solution for the questions that matter.
  • [0-5] Our organic, local, referral, directory and industry presence reflects the audience journey.
  • [0-5] Competitive visibility gaps are measured against a defined comparison set.
Answerability
  • [0-5] Our pages state direct, accurate answers near the beginning.
  • [0-5] People, services, evidence and organizational relationships are explicit and consistent.
  • [0-5] Search and AI systems can retrieve facts without inferring beyond the page.
Citability
  • [0-5] Authoritative third parties describe our organization accurately.
  • [0-5] AI engines cite relevant sources that support our authority position.
  • [0-5] We track citation context, source quality and competitor ownership.
Clinical and market credibility
  • [0-5] Material claims have named authors, reviewers, sources, dates and limitations.
  • [0-5] Credentials and expertise are independently verifiable.
  • [0-5] Promotional language does not exceed the supporting evidence.
Decision-path presence
  • [0-5] Patients, referral partners and buyers encounter the proof required at each material stage.
  • [0-5] Hidden stakeholders and stopping questions have been mapped.
  • [0-5] Audience-specific next actions are visible and appropriate.
Commercial continuity
  • [0-5] Visibility connects to qualified actions and owned handoffs.
  • [0-5] Response, referral, sales and CRM processes preserve context.
  • [0-5] Commercial results feed back into content and visibility priorities.
Interpret the result

Use the approved operational ranges: 0-39 major visibility discontinuity; 40-59 fragmented visibility; 60-74 functional but uneven visibility; 75-89 strong visibility with defined gaps; 90-100 highly consistent visibility within the assessed scope. These ranges are not market percentiles or clinical-quality ratings.

Executive discussion questions
  • Which audience and decision path does the weakest dimension affect?
  • What evidence supports the score, and what contradicts it?
  • What happens commercially if the gap remains?
  • Is the intervention reversible, and what evidence grade does it require?
  • What signal would justify scaling or reopening the decision?

What to do with a low self-score

Do not respond to a low total by launching six workstreams. Identify the dimension connected to the most material current decision and inspect the evidence behind the weak statements. If the problem is missing information, collect it before commissioning content. If the problem is weak substantiation, fix the claim and source architecture before increasing visibility. If the problem is a broken buyer or referral path, assign the operating owner who controls that handoff. The scorecard is useful only when it narrows the next decision rather than generating a longer marketing backlog.

Record the current rating, supporting evidence, accountable owner and review date before making the change. On the next review, rescore only from evidence that now exists. A self-score can show where leadership confidence exceeds visible proof, but it should not be converted into a formal Index score or competitor claim without the defined collection and review process in the methodology.

Frequently asked questions

No. It is an executive self-assessment. A formal Index score requires defined scope, reproducible collection, indicator scoring, review and an evidence-confidence grade.

Yes. Each contributes 16.67 points.

No. Competitive comparison requires aligned scope and evidence collection.

No. It assesses whether evidence is visible and verifiable.

Evidence and supporting sources

Implementation references

Bullzeye framework links